1 day Ago By ABMN Staff
Renaissance Technologies LLC lowered its stake in shares of Nevro Corp. ( NYSE:NVRO – Free Report ) by 5.2% during the fourth quarter, HoldingsChannel.
com reports. The firm owned 300,309 shares of the medical equipment provider’s stock after selling 16,610 shares during the period. Renaissance Technologies LLC’s holdings in Nevro were worth $1,117,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in NVRO. Amundi purchased a new position in shares of Nevro in the 4th quarter worth $30,000. Virtu Financial LLC purchased a new position in shares of Nevro in the 3rd quarter worth about $63,000.
Headlands Technologies LLC acquired a new position in shares of Nevro in the 4th quarter valued at about $45,000. Ieq Capital LLC acquired a new position in shares of Nevro in the 4th quarter valued at about $46,000. Finally, SG Americas Securities LLC grew its holdings in shares of Nevro by 34.
6% during the 4th quarter. SG Americas Securities LLC now owns 17,126 shares of the medical equipment provider’s stock worth $64,000 after purchasing an additional 4,406 shares during the period. Institutional investors and hedge funds own 95.
52% of the company’s stock. Nevro Stock Performance Shares of NVRO opened at $5.85 on Wednesday.
Nevro Corp. has a 52-week low of $3.17 and a 52-week high of $11.
79. The company has a quick ratio of 3.76, a current ratio of 5.
02 and a debt-to-equity ratio of 0.67. The firm has a market cap of $224.
32 million, a price-to-earnings ratio of -3.09 and a beta of 0.81.
The business’s 50 day moving average is $5.81 and its two-hundred day moving average is $5.06.
Analysts Set New Price Targets A number of brokerages have weighed in on NVRO. Piper Sandler raised shares of Nevro from a “neutral” rating to an “overweight” rating and reduced their price target for the company from $6.00 to $5.
85 in a research report on Friday, February 7th. StockNews.com initiated coverage on shares of Nevro in a report on Wednesday, April 23rd.
They set a “hold” rating on the stock. Jefferies Financial Group raised shares of Nevro from an “underperform” rating to a “hold” rating and upped their price target for the stock from $4.50 to $5.
85 in a research report on Monday, February 10th. Finally, Canaccord Genuity Group boosted their price objective on Nevro from $4.00 to $5.
85 and gave the stock a “hold” rating in a research note on Friday, February 7th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat, Nevro presently has an average rating of “Hold” and an average price target of $5.
36. Check Out Our Latest Stock Report on NVRO About Nevro ( Free Report ) Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally.
The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. Featured Articles Want to see what other hedge funds are holding NVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nevro Corp.
( NYSE:NVRO – Free Report ). Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter .
.
